Matzkin H - Search Results

1

Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.

Elhilali M, Emberton M, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Alcaraz A, Vallancien G; ALF-ONE Study Group. Elhilali M, et al. Among authors: matzkin h. BJU Int. 2006 Mar;97(3):513-9. doi: 10.1111/j.1464-410X.2005.05962.x. BJU Int. 2006. PMID: 16469018

2

Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.

Hartung R, Matzkin H, Alcaraz A, Emberton M, Harving N, van Moorselaar J, Elhilali M, Vallancien G; ALF-ONE Study Group. Hartung R, et al. Among authors: matzkin h. J Urol. 2006 Feb;175(2):624-8; discussion 628. doi: 10.1016/S0022-5347(05)00155-2. J Urol. 2006. PMID: 16407011

3

Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.

Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, Alcaraz A, Vallancien G; Alf-One Study Group. Emberton M, et al. Among authors: matzkin h. Urology. 2005 Aug;66(2):316-22. doi: 10.1016/j.urology.2005.03.024. Urology. 2005. PMID: 16098361

4

Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G. Emberton M, et al. Among authors: matzkin h. J Urol. 2006 Sep;176(3):1051-6. doi: 10.1016/j.juro.2006.04.044. J Urol. 2006. PMID: 16890690

5

Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.

Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M; ALF-ONE Study Group. Vallancien G, et al. Among authors: matzkin h. BJU Int. 2008 Apr;101(7):847-52. doi: 10.1111/j.1464-410X.2008.07458.x. BJU Int. 2008. PMID: 18321317

6

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.

van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M, Alcaraz A, Vallancien G; ALF-ONE Study Group. van Moorselaar RJ, et al. Among authors: matzkin h. BJU Int. 2005 Mar;95(4):603-8. doi: 10.1111/j.1464-410X.2005.05347.x. BJU Int. 2005. PMID: 15705088 Clinical Trial.

7

Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study.

Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Chen J, et al. Among authors: matzkin h. BJU Int. 1999 Feb;83(3):269-73. doi: 10.1046/j.1464-410x.1999.00906.x. BJU Int. 1999. PMID: 10233492 Clinical Trial.

8

Endourological procedures and sexual dysfunction: a prospective multivariate analysis.

Sofer M, Yehiely R, Greenstein A, Bar-Yosef Y, Matzkin H, Chen J. Sofer M, et al. Among authors: matzkin h. BJU Int. 2012 Jan;109(2):250-3. doi: 10.1111/j.1464-410X.2011.10232.x. Epub 2011 Apr 20. BJU Int. 2012. PMID: 21507192

9

Does information provided to men before a urodynamic study affect their expectation of pain?

Greenstein A, Bar-Yosef Y, Chen J, Matzkin H. Greenstein A, et al. Among authors: matzkin h. BJU Int. 2005 Dec;96(9):1307-9. doi: 10.1111/j.1464-410X.2005.05828.x. BJU Int. 2005. PMID: 16287450

10

Efficacy of terazosin in patients with benign prostatic hyperplasia.

Matzkin H, Soloway MS, Rangel MC, Laddu A. Matzkin H, et al. Eur Urol. 1992;21(2):126-30. doi: 10.1159/000474817. Eur Urol. 1992. PMID: 1379921 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters